Goldman Sach's issues a sell recommendation in February 2011, which was followed up by two out of three negative press releases by the company. What is especially troubling is yesterday's news. I don't understand how antibodies can all of a sudden become an issue for Pramlintide + Leptin after multiple clinical studies have already been completed. What's even more troubling is the fact that Amylin stated that the antibodies were found in only 2 patients from a previous already completed trial and that they were voluntarily suspending a Phade II trial which was only started a month ago. I am troubled by the sequence of events starting with the Goldman Sac announcement and folllowed by Amylin's subsequent press releases which highlighted negative news. Seems to me the Victoza-6 news could have been deferred until the entire trial results were known to offer a more balanced picture and the voluntary suspension of the Phase II trial for Pram + Lep is just altogehter mysterious. There could be a perfectly good explantion for the recent choices Amylin has made surrounding their PR initiatives, however, the lack their lack of transparancy leaves the door open to speculation about their motives. The timing of everything just doesn't look good.